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To explore how heparan sulfate (HS) controls the re-
sponsiveness of the breast cancer cell lines MCF-7 and
MDA-MB-231 to fibroblast growth factors (FGFs), we
have exposed them to HS preparations known to have
specificity for FGF-1 (HS glycosaminoglycan (HSGAG
A)) or FGF-2 (HSGAGB). Proliferation assays confirmed
that MCF-7 cells were highly responsive to FGF-2 com-
plexed with GAGB, whereas migration assays indicated
that FGF-1/HSGAGA combinations were stimulatory for
the highly invasive MDA-MB-231 cells. Quantitative po-
lymerase chain reaction for the levels of FGF receptor
(FGFR) isoforms revealed that MCF-7 cells have greater
levels of FGFR1 and that MDA-MB-231 cells have greater
relative levels of FGFR2. Cross-linking demonstrated
that FGF-2/HSGAGB primarily activated FGFR1, which
in turn up-regulated the activity of mitogen-activated
protein kinase; in contrast, FGF-1/HSGAGA led to the
phosphorylation of equal proportions of both FGFR1
and FGFR2, which in turn led to the up-regulation of Src
and p125FAK. MDA-MB-231 cells were particularly re-
sponsive to vitronectin substrates in the presence of
FGF-1/HSGAGA, and blocking antibodies established
that they used the avb3 integrin to bind to it. These
results suggest that the clustering of particular FGFR
configurations on breast cancer cells induced by differ-
ent HS chains leads to distinct phenotypic behaviors.
Members of the fibroblast growth factor (FGF)1 family have
been shown to be intimately involved in such diverse processes
as germ layer formation, neurogenesis, angiogenesis, and
wound healing (1–4). They are also involved in many forms of
cancer cell growth and metastasis (5, 6). There have been at
least 17 different isoforms of this factor so far described, and
one of the major themes of FGF biology has been the ongoing
effort to discover how each factor delivers a biologically rele-
vant signal in ways that are tissue-specific. This problem is
compounded by the fact that there are four different major
forms of FGF receptor (FGFR) tyrosine kinase, each of which
can be spliced by differential exon usage into multiple species
(7, 8). Exactly which form of FGF binds to which FGFR to drive
a particular biological outcome in any tissue remains unclear.
It is known that FGFs use an accessory form of receptor to
bind to their cognate cell-surface receptors more efficiently.
These are heparan sulfate (HS) glycosaminoglycan (HSGAG)
sugars, which are usually found as part of transmembrane or
cell-associated proteoglycan complexes (9). Exactly how HS
interacts with the FGFs so that they can bind to their high
affinity receptors remains controversial (7); it may simply be
the case that they passively dimerize the FGFs, or FGFRs, so
that signal transduction can occur (10). Recently, more inter-
esting hypotheses have asserted that domains within HS
chains are able to cross-link FGFs with FGFRs to form acti-
vated ternary complexes (11–17), perhaps with some measure
of specificity (18–21). This is coincident with the variable ex-
pression of FGFRs as either long three-Ig loop forms or shorter
two-loop forms seen more often in malignant cells (22); the
shorter forms of receptor bind HS more avidly and are thus
activated more easily than the native longer forms.
FGFs, particularly the archetypal forms FGF-1 and FGF-2,
have been detected within human breast tumors as well as
normal breast epithelial and myoepithelial cells (23–26). They
have been identified within developing mammary glands both
in rodents and humans (27). FGF-2 is mitogenic for breast
epithelial cell lines such as MCF-7 and T-47D, although hor-
mone-independent MDA-MB-231 cells do not become sensitive
to FGFs until inhibitory HS is removed from their surfaces by
chlorate treatment (28). Biochemical purification of HS from
both MCF-7 and MDA-MB-231 cells reveals very different HS
profiles, lending support to the idea that the behavior of breast
tumor cells in an FGF-rich environment is contingent upon
these accessory sites (28). This hypothesis has recently re-
ceived important support from biosensor assays (29), where it
was found that FGF-2-binding HS occurred with two separable
activities: one strongly held FGF-2 away from cognate cell
receptors, and the other, of lower affinity, appeared to be per-
missive for FGF-2 and its receptors.
We have previously purified forms of HS from a neuroepi-
thelial cell line that have affinities for either FGF-1 or FGF-2,
depending on the phenotypic state of the cells (19, 20, 30).
When the cells are maintained in proliferative phase, their HS
chains remain relatively short and moderately sulfated; as they
begin to differentiate, the chains become longer and more com-
plex, with greater degrees of sulfation. These chains have been
purified and shown to have FGF-potentiating activity on a wide
variety of other cell types, including amphibian cells (31).
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The aim of this study was to explore the differences in re-
sponse to FGFs that could be induced in breast cancer cells by
HS preparations with known specificities. Proliferation and
migration assays were carried out on MCF-7 and MDA-MB-231
cells in the presence of GAGA, which potentiates the actions of
FGF-1, or GAGB, which potentiates FGF-2 (20). FGFR profiles
for each cell type were obtained by RT-PCR, and the activation
of the receptors by FGF/GAG combinations was monitored by
cross-linking, immunoprecipitation, and phosphotyrosine as-
says. The results indicate that the different HS preparations
activate different combinations of FGFRs, which in turn leads
to differential activation of MAPK, Src, FAK, and integrins and
thus rates of breast cancer proliferation and migration. We
conclude that HSGAGB interacts with FGF-2 to drive prolifer-
ation through FGFR1 and that HSGAGA interacts with FGF-1
to drive a mixed proliferation and migration signal through
FGFR1/FGFR2 association. We conclude that extracellular HS
can help direct the phenotypic behavior of breast cancer cells
through the differential activation of FGFRs.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human FGF-1 and FGF-2 were from either
Sigma or Amgen. Minimal essential medium, fetal calf serum, HEPES,
nonessential amino acids, penicillin, streptomycin, and trypsin/EDTA
solutions were from Commonwealth Serum Laboratories (Melbourne)
or eurobio (Paris). The Titan One-Step PCR system was from Roche
Molecular Biochemicals. The digital image analysis system was from
Zolltec (Iowa City). Anti-FGFR antibodies were from Santa Cruz Bio-
technology, and anti-phosphotyrosine 4G10 antibodies were from Up-
state Biotechnology, Inc. The isolation of HS chains with specificities for
FGF-1 and FGF-2 has been fully described previously (18–20); ;2 mg of
each HS species was required for this study. Briefly, 8 3 107 cells from
40–60 mice embryos of the appropriate ages were cultured in serum-
free medium for harvesting and fractionation. The conditioned medium
from either the embryonic day 10 or 12 cells was chromatographed on
DEAE-Sephacel, and fractions were treated with neuraminidase, chon-
droitin ABC lyase, and Pronase. HS chains were removed from the core
protein with NaBH4, and samples were run on Sepharose CL-6B col-
umns for sizing of the released HS chains. [3H]Thymidine and [35S]cys-
teine/methionine were from ICN. Heparitinase I (heparin-sulfate lyase,
EC 4.2.2.8) was obtained from Seikagaku Kogyo Co. (Tokyo). Western
blot bands were visualized with ECL1 reagents (Amersham Pharmacia
Biotech) and quantitated on a Storm Fluorimager (Molecular Dynam-
ics, Inc.) using NIH ImageQuant software. Disuccinimidyl suberate
(DSS) cross-linker was from Pierce. Integrin anti-a and anti-b subunit
antibodies were from Upstate Biotechnology, Inc. and Life Technolo-
gies, Inc. Heparin (low molecular mass) was from Sigma. Matrigel was
from Calbiochem.
Cell Culture—The human breast tumor cell lines MCF-7 and MDA-
MB-231 were obtained from the American Type Culture Collection and
routinely grown as monolayer cultures. They were maintained in im-
proved modified Eagle’s medium containing 10% heat-inactivated fetal
calf serum, 20 mM HEPES, 2 g/liter sodium bicarbonate, 2 mM L-
glutamine, 100 IU/ml penicillin/streptomycin, 50 mg/ml gentamycin
sulfate, 1% nonessential amino acids, and 5 mg/ml insulin. Cells were
maintained in 5% CO2 in a humidified atmosphere at 37 °C. Cultures
were washed three times in modified Eagle’s medium and replaced with
medium containing the appropriate ligands. Cells in exponential phase
growth were washed twice with phosphate-buffered saline and starved
for 24 h in fresh serum-free medium containing transferrin (30 mg/ml).
Either FGF-1 or FGF-2 was then added at 5 ng/ml with nominated
amounts of HS, and the cells were incubated for 24 h in 24-well plates.
By this point S phase synthesis had reached a maximum, and 1.5 mM
[3H]thymidine was added to the cultures for a further 1 h; cells were
then prepared for scintillation counting (19). In some experiments,
MDA-MB-231 cells were pretreated with heparitinase I (0.05 IU/ml) for
3 h prior to the assay, with the same dose added upon addition of the
FGF/HS combinations and every 8 h through the 24-h assay period.
Cell Migration Assays—Cells (2 3 105) were plated onto Matrigel-
coated substrates (32) in 35-mm plastic tissue culture dishes and al-
lowed to settle and adhere for 30 min within an incubator. They were
then removed to a heated stage within a CO2-controlled environment
surrounding an Olympus IM35 inverted phase microscope. Cells were
monitored over 150 min by time-lapse video recording (Panasonic
TL260 set at 1 frame/6 s capture rate). Rates of cell movement were
assessed by the digital image analysis system, which converted the
video into the Quicktime format. The movement of 50 cells per treat-
ment was assessed, and the whole experiment was repeated twice.
To assess which integrin receptor class might be involved in migra-
tion, anti-integrin blocking antibodies (100 mg/ml) were added to the
medium as the cells were placed in the controlled environment sur-
rounding the microscope stage. Movement was assessed as described
above. To confirm specific blocking by the antibodies, cells were cul-
tured on murine vitronectin, laminin, thrombospondin, or collagen IV
(Sigma; all applied at a coating concentration of 10 mg/ml in phosphate-
buffered saline for 2 h at room temperature). These were coated over a
control layer of poly-L-ornithine (32) in the presence of soluble FGF/HS
ligand combinations.
FGFR Isoform Quantitation—Amounts of each of the FGFR IIIb and
IIIc isoforms were assessed by quantitative RT-PCR using the same
primers as described previously (19). In addition, an extra primer
spanning an intron (59-AAGTCTCAGTAATCCTCTCAATCG-39), di-
rected against the N terminus of FGFR1, was used to assess the
amounts of long three-Ig loop FGFR1 forms as opposed to the shorter
two-Ig loop forms. Briefly, MDA-MB-231 and MCF-7 cells (5 3 107)
were maintained in serum-free medium in 10-cm plastic dishes for 24 h,
and their RNAs were extracted with TriPure Isolation reagent (Roche
Molecular Biochemicals). RT-PCR (Titan One-Tube, Roche Molecular
Biochemicals) was then performed with the appropriate receptor iso-
form primers. The same RNA batch preparation was used for all the
FGFR determinations within a series. Each receptor isoform RNA iso-
late was then independently assessed for optimal cycling conditions for
amplification, both by varying total RNA concentration and the number
of amplification cycles according to the manufacturer’s instructions.
The cycling conditions for amplification were 2 min at 94 °C; 10 cycles
at 94 °C for 30 s; annealing at 52 °C for 30 s; elongation at 68 °C for 45 s,
followed by prolonged elongation for 7 min for 68 °C. For FGFR1, for a
set 0.5 mg of total RNA, signals were in the linear range for 17–28
cycles; for FGFR2, 22–33 cycles; for FGFR3, 21–28 cycles; and for
FGFR4, 35–45 cycles. Determination of the levels of PCR product was
by capillary electrophoresis through 0.2-mm polyacrylamide-coated cap-
illaries in a P/ACE System 2100 (Packard Instrument Co.) using laser-
induced fluorescence (argon laser at 488 nm, with the emission collected
through a band-pass filter at 520 nm using the exact method in the
manufacturer’s instructions (Roche Molecular Biochemicals)). Injection
of samples was over 60 s, with separation at 175 V/cm. Levels of
expression were quantified by integrating peak areas in relative fluo-
rescence units for the primers (i.e. the PCR product as compared with
the total fluorescence).
Receptor Activation—Binding of FGF/HSGAG combinations was car-
ried out essentially according to the methods of Spivak-Kroizman et al.
(33). Briefly, 5 3 106 cells, pre-exposed to [35S]cysteine/methionine for
18 h, were washed and resuspended in serum-free medium and exposed
to different FGF/HSGAG combinations as described below. Some prep-
arations of MDA-MB-231 cells were treated with heparitinase I as
detailed above to remove inhibitory HS species that might interfere
with the binding results. After 60 min in the presence of the cross-linker
DSS (0.3 mM in Me2SO), the cells were pelleted (800 rpm for 5 min),
lysed on ice (150 mM NaCl, 50 mM Tris, 0.1% SDS, 1% Triton X-100, 10%
glycerol, 1.5 mM MgCl2, 2 mM benzamide, 2 mM N-ethylmaleimide, 1 mM
EDTA, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mM phenylmethyl-
sulfonyl fluoride), and centrifuged for 5 min at 4 °C. The protein con-
centrations in the clarified lysates were determined with the BCA
protein assay reagent (Bio-Rad). Lysates were then immunoprecipi-
tated with anti-FGFR1, anti-FGFR2, anti-FGFR3, or anti-FGFR4 an-
tibodies according to the methods of Lin et al. (34); boiled (5 min); and
subjected to 5% SDS-PAGE. Gels were electroblotted onto nitrocellu-
lose, and receptor complexes were revealed by autoradiography using
Kodak XAR film. Bands were analyzed with NIH ImageQuant software.
Some cells in suspension were exposed to various FGF/HS combina-
tions for a period of 5–30 min and lysed as described above. Lysates
were clarified by the addition of protein A-Sepharose 4B (Pansorbin,
Calbiochem), followed by centrifugation and protein concentration de-
termination. Aliquots of the supernatant of each sample (1 mg) were
incubated with anti-FGFR antibodies for 1 h on ice. Pansorbin was
added for an additional 30 min, and the pellets were collected by
centrifugation, washed, boiled in sample buffer, and subjected to SDS-
PAGE. Gels were electroblotted onto nitrocellulose, and the membranes
were probed with anti-phosphotyrosine monoclonal antibody 4G10
overnight at 4 °C, rinsed, and incubated with a horseradish peroxidase-
conjugated anti-mouse IgG (Sigma) for 2 h at room temperature. Mem-
branes were washed and visualized as described above with the ECL1
reagent.
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Kinase Assays—MAPK activity was determined by immunoprecipi-
tation of lysates with anti-ERK1 and anti-ERK2 antibodies as described
above and revealed on gels with an in vitro assay using myelin basic
protein (MBP) as a substrate, where the phosphorylated myelin basic
protein was visualized by autoradiography (35). Src kinase activity was
determined by immunoprecipitation with anti-Src monoclonal antibody
327 (35). The antibody complexes were washed three times with lysis
buffer and once with kinase buffer (30 mM Tris (pH 7.4) and 10 mM
MnCl2) and were subsequently incubated in 50 ml of kinase buffer
containing 10 mCi of [g-32P]ATP and 2 mg of acid-denatured enolase
(Sigma) at room temperature for 10 min. The phosphorylated proteins
were resolved by 7.5% SDS-PAGE, transferred to nitrocellulose, and
visualized by autoradiography. Subsequently, immunoblot analysis was
performed using the anti-Src-2 antibody (35). The activity of FAK was
assessed by immunoprecipitation of cell lysates with rabbit anti-mouse
FAK antibody (Sigma) and immunoblotting with anti-phosphotyrosine
monoclonal antibody 4G10.
RESULTS
Effect of HS on Breast Epithelial Cell Proliferation—The
effects of various concentrations of HSGAGs on the response of
cells to FGF-1 or FGF-2 in serum-free medium were assessed
by both microscopic examination (Fig. 1) and thymidine incor-
poration after 24 h of exposure. The stimulatory effect of the
HSGAGs was dose-dependent, although they had a much
greater effect on the MCF-7 cells than on the MDA-MB-231
cells (Fig. 2). The greatest potentiating effect of HSGAGB on
MCF-7 cells was reached at 5 mg/ml with an FGF-2 concentra-
tion of 5 ng/ml; at higher levels, its potentiating effects began to
decline, consistent with it now interfering with the access of the
growth factor to the cell surface. In all cases, where the incor-
rect combination of FGF-2/HSGAGA or FGF-1/HSGAGB was
used, no effects were seen above controls. The stimulatory
effects of HSGAGA and FGF-1 on MCF-7 cells were not as
dramatic as those of HSGAGB, but were greater than controls.
The effects of HSGAGs and FGFs on native MDA-MB-321 cells
were very much less than those on MCF-7 cells, indeed almost
negligible, consistent with previous findings that demonstrated
an endogenous, FGF-inhibitory HS species associated with
these cells (28). Although pretreating the cells with hepariti-
nase I reduced the inhibitory effects of endogenous HS on the
cells, an effect noted by Rahmoune et al. (29) after sodium
chlorate treatment, the HSGAG potentiation was less than for
the MCF-7 cells. We used low concentration heparitinase I
treatment here as a milder and more specific form of removal of
these endogenous inhibitory HS sequences and maintained it
in the medium during treatment with the FGF/HSGAG com-
binations. Although it is likely that the maintained hepariti-
nase I treatment affects the exogenous experimental HSGAGs,
we have previously shown it to liberate active, FGF-binding
GAG subdomains from HS chains (18–20). Nonetheless, it was
clear with these cells that the FGF-2/HSGAGB combination
provided a greater drive for proliferation than did the FGF-1/
HSGAGA combination.
Cell Migration Assays—The addition of FGF-1/GAGA to sub-
strates led to noticeable changes in the cell morphologies of
both the MCF-7 and MDA-MB-231 cells; the cells became much
more stellate, with greater proportions of lamellipodia and
filopodia and trailing edges (Fig. 1). As this influence seemed to
be a stimulus for cells to move, we quantitated rates of cell
migration on different FGF/HS combinations with time-lapse
photomicrography. Dispersed cells were plated onto either des-
ignated FGF/HS-coated substrates or Matrigel and allowed to
adhere, and their movements were recorded over the following
150 min. These tapes were then processed through the digital
image analysis system. The cells showed by far the greatest
migratory behavior in medium containing FGF-1/HSGAGA.
Although this effect was greatest for the highly motile MDA-
MB-231 cells, it could also be seen in the more quiescent MCF-7
cells (Fig. 3). Increases in motility were seen on HSGAGA or
FGF-1 alone, but the effects of their combination were additive
and led to noticeably greater migratory speeds. Interestingly,
these speeds were not maintained over the 150 min, but pla-
teaued out after ;60 min. In contrast, the motility observed
when either MCF-7 or MDA-MB-231 cells were exposed to
FGF-2, either alone or in combination with HSGAGB, was
barely above control levels. In all cases where the incorrect
combination of FGF-2/HSGAGA or FGF-1/HSGAGB was used,
no effects were seen above controls.
Receptor Profiles—An RT-PCR assay designed specifically to
detect the expression of the IIIb and IIIc variant forms of the
FGFRs was used to analyze the expression of these isoforms in
the breast cells essentially as described previously (19), except
that the quantitation was accomplished by laser-induced fluo-
rescence after capillary electrophoresis. Although differential
splicing within the FGFR genes generates many variants
within a single receptor type, splicing events that particularly
influence receptor affinity for a specific FGF involve the C-
terminal half of the Ig-like loop III in the extracellular domain.
Studies on the genomic organization of FGFR1, FGFR2, and
FGFR3 have shown that each of these genes contains two
exons, b and c, which lie in close proximity to each other and
can be alternatively spliced into the C-terminal half of loop III
to generate an FGFR IIIb or IIIc variant (36–39). RT-PCR was
performed for quiescent non-confluent cells with different com-
binations of primer pairs (double determinations; data not
shown), and calibration curves for each FGFR isoform were
established with varying numbers of cycles for each primer
combination (data not shown). Measured points from the dif-
ferent cycle combinations deviated very little, proved quite
robust, and confirmed the fidelity and accuracy of the system.
The levels of FGFR IIIb and IIIc loop expression for each of
the receptor forms proved to be distinctive for both MCF-7 and
MDA-MB-231 cells (Fig. 4). MCF-7 cells expressed much higher
FIG. 1. Morphologies of MCF-7 cells plated onto poly-L-orni-
thine substrates for 24 h in the presence of different FGF/HS
combinations as revealed by phase-contrast microscopy. A, con-
trol MCF-7 cells; B, MCF-7 cells plated in the presence of the incorrect
combination FGF-2/HSGAGA; C, MCF-7 cells plated in the presence of
the appropriate combination FGF-2/HSGAGB; D, MCF-7 cells plated in
the presence of FGF-1 alone; E, MCF-7 cells plated in the presence of
the incorrect combination FGF-1/HSGAGB; F, cells plated in the pres-
ence of the appropriate combination FGF-1/HSGAGA (note the elon-
gated, stellate forms). In all cases where the incorrect combination of
FGF-2/HSGAGA or FGF-1/HSGAGB was used, no effects were seen
above controls. Bar 5 50 mm.
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levels of FGFR1 IIIb and IIIc than the FGFR2 or FGFR3 forms.
In contrast, the MDA-MB-231 cells had greater levels of
FGFR2 than FGFR1, especially of the FGFR2 IIIc form; the
differences in expression levels were not nearly so marked as
for the FGFR IIIb forms. To examine whether full-length
FGFR1 or shorter forms were being expressed, we designed an
extra primer corresponding to the bases coding for the first
eight N-terminal amino acids of the full-length receptor (prim-
er 11) and used it in PCR (40 amplification cycles) with primer
6. The signal was compared with that generated for the IIIb
and IIIc signals, and the relative levels of short and long forms
were calculated as proportions of 100%. The results show that,
for FGFR1, the proliferative MCF-7 cells have much greater
proportions of long three-Ig-like loops rather than shorter two-
loop forms; in contrast, the slowly proliferating, but highly
invasive MDA-MB-231 cells have a much greater proportion of
shorter forms of FGFR1.
Receptor Clustering Induced by Different HS Prepara-
tions—To examine the FGFRs being recruited and stimulated
by the FGF/HS combinations, immunoprecipitations were per-
formed after cross-linking the ligand combinations to cell sur-
faces with DSS (Fig. 5). Cells were maintained in [35S]cysteine/
methionine for 18 h and then exposed to ligand concentrations
for 60 min and cross-linked; the cells were lysed, and the
receptors were immunoprecipitated with specific antibodies.
The results demonstrated that for native MCF-7 cells, the
FGF-2/HSGAGB combination led to the immunoprecipitation
of FGFR1 alone; this was seen, albeit at much lower levels,
even if HSGAGB was used by itself without exogenous FGF-2.
Similarly, the addition of DSS by itself as control, without
either FGF or HSGAG, did not lead to receptor patterns any
different from those brought down in response to FGF alone,
although band intensity was up to 8-fold less as quantitated by
image analysis. A similar, although less intense result was also
seen if untreated MDA-MB-231 cells were used (data not
shown). Receptor monomers were also precipitated by the an-
tibodies in these experiments; in contrast to the cross-linked
dimers, which ran at just under 300 kDa on gels, the monomers
ran at under 200 kDa. Monomer bands were never seen on
blots probed with anti-phosphotyrosine antibodies.
The results were distinctly different when cells were exposed
to FGF-1/HSGAGA combinations. This combination led to the
immunoprecipitation of approximately equal amounts of
FGFR1 and FGFR2. A very much weaker (11-fold), but sub-
stantially similar signal was seen if just HSGAGA was used
(data not shown). When incorrect FGF and HS pairs were used,
such as FGF-1/HSGAGB, no receptor cross-linking could be
detected; a minor amount of FGFR1 could be detected in re-
sponse to the unspecific FGF-1/HSGAGB pairing if the blot was
exposed to film for .3 weeks.
To confirm that the cross-linked receptors were active, we
examined the influence of HS on the ability of FGF-1 and
FGF-2 to stimulate the phosphorylation of FGFR1 and FGFR2
(Fig. 5B). Cell lysates were prepared as described above from
unlabeled cells that had been exposed to different FGF/HS
combinations, immunoprecipitated with anti-FGFR antibodies,
subjected to SDS-PAGE, and electroblotted; and the gels were
probed with anti-phosphotyrosine antibodies. The results dem-
onstrated that the FGFR1 that cross-linked to FGF-2/HSGAGB
was phosphorylated as a result; in contrast, both FGFR1 and
FGFR2 were phosphorylated in the receptor clusters cross-
linked to FGF-1/HSGAGA. The phosphorylation results there-
fore closely mirrored the receptor coupling results. Despite the
apparent disparities between FGFR1 and FGFR2 densities for
both cell types, HSGAGA appeared to result in approximately
equal amounts of phosphorylation for FGFR1 and FGFR2. Sub-
stantially similar results were seen with the MDA-MB-231
cells. Again, in cases where the incorrect combination of FGF-
2/HSGAGA or FGF-1/HSGAGB was used in either assay, no
selectivity different from growth factor treatment alone was
seen in either the binding or activation assays (data not
shown).
FIG. 2. Dynamics of DNA synthesis in MCF-7 or MDA-MB-231 cells maintained in FGF/HS ligand combinations for 24 h and
tritiated thymidine for the last hour. Native MCF-7 cells (black bars) or heparitinase I-pretreated MDA-MB-231 cells (white bars) were left
alone (control (Con)) or exposed to porcine heparin alone (5 mg/ml), to HSGAGB or HSGAGA alone (5 mg/ml), to FGF-2 alone (5 ng/ml), to FGF-2
and nonspecific heparin (5 ng/ml to 5 mg/ml), to FGF-2 with the incorrect HSGAGA (50 mg/ml), or to increasing levels of HSGAGB in the presence
of a fixed FGF-2 concentration (5 ng/ml). Analogous experiments were carried out on the two cell types with FGF-1. The pretreatment was used
to try to nullify the effects of endogenous inhibitory HS species on this cell type.
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Kinase Regulation by Different HS Preparations—FGF-1 and
FGF-2 are able to induce the tyrosine phosphorylation of many
intracellular second messenger candidates. For example, it has
previously been demonstrated that the interaction of FGF-1
with FGFR1 up-regulates MAPK activation through both the
Ras and phospholipase Cg pathways (40). To investigate the
effects of the FGF/HS ligand pairs on activation of p44mapk and
p42mapk, we examined their levels of tyrosine phosphorylation
after immunoblotting (Fig. 6). Exposure of cells to FGF-2/HS-
GAGB resulted in substantially greater levels of phosphoryla-
tion of both p44mapk and p42mapk,for MCF-7 cells and either
heparitinase I-treated or native MDA-MB-231 cells (although
the first two showed by far the greater proportional increases).
The levels were greater than cells exposed to the FGF-2/hepa-
rin combination and markedly greater than for either FGF-2 or
HSGAGB alone. The levels of p44mapk and p42mapk triggered by
FGF-1/HSGAGA were greater than those triggered by control
conditions, but still only about half those provided by FGF-2/
HSGAGB. This result was also seen with the heparitinase
I-treated MDA-MB-231 cells.
FGFs are also known to induce the tyrosine phosphorylation
of Src, which then feeds into a number of pathways, including
the control of extracellular adhesion through the FAK pathway
(41). Because the Src protein can be phosphorylated on tyrosine
in an inactive as well as an active state (42), we used an in vitro
kinase assay in the manner of LaVallee et al. (35) to determine
the effects of FGF/HS combinations on Src activity. In contrast
to the results seen with MAPK, the FGF-1/HSGAGA combina-
tion was much more effective in increasing Src than the FGF-
2/HSGAGB combination both for the MCF-7 cells as well as the
heparitinase I-treated and native MDA-MB-231 cells (Fig. 7).
The results for Src activation as well as the higher migration
rates of cells on FGF-1/HSGAGA substrates led us to examine
the regulation of the intermediary protein species FAK (Fig. 8).
It is known to be involved in the formation of focal adhesion
plaques where cortical actin has been brought into register
with the activated intracellular cytoplasmic domains of mem-
bers of the integrin receptor superfamily (41). Consistent with
the specificity of FGF-1/HSGAGA effects in preferentially up-
regulating Src over MAPK pathways, we found a very marked
increase in the levels of phosphorylated FAK; this was partic-
ularly so in the MDA-MB-231 cells left untreated by hepariti-
nase I. These latter cells are noticeable for their lack of re-
sponse to stimuli including FGF-2, in part due to their
endogenous complement of inhibitory HS (28, 29). There were
no major changes in the general FAK pool under any of the
conditions tested.
Integrin Receptor Blockade—As the FAK pathway is a key
regulatory element in the intracellular adhesion triggered by
integrin receptors, we next attempted to determine whether
there was any specificity in the adhesion signals triggered by
the increase in Src and FAK in response to FGF-1/HSGAGA or
FGF-2/HSGAGB. The FGF/HS combinations were applied to
the cells in soluble rather than substrate-fixed form. The cells
FIG. 3. Migration assays for MCF-7
and MDA-MB-231 cells plated onto
Matrigel substrates for 150 min in the
presence of different FGF/HS combi-
nations. FGFs were present at 5 ng/ml,
and HS was present at 5 mg/ml. Move-
ment rates of cells were quantitated after
time-lapse video photomicrography, digi-
tal conversion, and processing through
image analysis. A, MCF-7 cells exposed to
FGF-2/HSGAGB (l ), HSGAGB alone (),
FGF-2 alone (E), the incorrect combina-
tion FGF-2/HSGAGA (l), or no additives
(); B, MDA-MB-231 cells exposed to
FGF-2/HSGAGB (l ), HSGAGB alone (),
FGF-2 alone (E), the incorrect combina-
tion FGF-2/HSGAGA (l), or no additives
(); C, MCF-7 cells exposed to FGF-1/HS-
GAGA (f), HSGAGA alone (black squares
with plus signs), FGF-1 alone (M), the
incorrect combination FGF-1/HSGAGB
(°), or no additives (1); D, MDA-MB-231
cells exposed to FGF-1/HSGAGA (f), HS-
GAGA alone (black squares with plus
signs), FGF-1 alone (M), the incorrect
combination FGF-1/HSGAGB (°), or no
additives (1). Each point is the average
(Ave.) of 50 determinations, and the S.D.
values on each point never exceeded 4% of
the mean. The entire experiment for each
condition was repeated at least twice.
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were plated onto extracellular matrix-rich Matrigel and moni-
tored with time-lapse photomicrography for 150 min in the
presence of specific integrin-blocking antibodies (Fig. 9). The
results demonstrated that FGFR1/FGFR1-utilizing cells use
different integrin combinations than FGFR1/FGFR2-utilizing
cells to bind to Matrigel in the presence of FGF-1/HSGAGA.
Cells utilizing FGFR1/FGFR1 used a6b1 (Fig. 9A), thought to
be a receptor for laminin (43), and cells utilizing FGFR1/
FGFR2 signaling used primarily avb3 dimer combinations (Fig.
9B), thought to be one of the receptors for vitronectin (44). To
explore this more fully, cells were plated onto substrates coated
with increasing concentrations of either laminin or vitronectin
(Fig. 9, C and D). The results demonstrated that movements for
the FGFR1/FGFR2-utilizing cells were up-regulated on
vitronectin substrates to a much greater degree than on lami-
nin in the presence of FGF-1/HSGAGA, but that the opposite
was true for FGFR1/FGFR1 cells. Interestingly, there was no
particular substrate preference when either cell type was mon-
itored in the presence of HSGAGB or FGF-2.
DISCUSSION
The results of this study demonstrate that breast cancer
epithelial cells will up-regulate their responses to FGFs when
they are presented in combinations with activating HS chains.
Furthermore, defined HS chains that potentiate the activities
of FGF-2 through FGFR1 lead to proliferation by up-regulating
the activities of the MAPK pathway. In contrast, defined HS
chains that up-regulate the activities of FGF-1 do so through
the signaling activities of FGFR1 and FGFR2 combinations,
which as well as up-regulating MAPK, up-regulate the activity
of Src and its downstream target FAK. This latter activity
correlates with an increase in the initial rates of cellular mi-
gration, which in turn correlates with the activity of particular
integrins, including the avb3 receptor in the case of MDA-MB-
FIG. 4. Determination of both the expression levels of FGFR isoforms as determined by RT-PCR/capillary electrophoresis/laser-
induced fluorescence and the proportions appearing as short (two-Ig loop) and long (three-Ig loop) forms. Note that FGFR4 (R4) has
only one isoform. RT-PCR products were quantified (in relative fluorescent units) and calibrated for each receptor isoform primer pair with
capillary electrophoresis/laser-induced fluorescence. Determination of PCR products by capillary electrophoresis was carried out in a P/ACE
System 2100 with laser-induced fluorescence detection by argon ion laser. Total RNA was extracted from quiescent non-confluent cells. A, receptor
levels for MCF-7 cells and the proportion of FGFR1 types appearing as short (S) or long (L) forms; B, receptor levels for MDA-MB-231 cells.
FIG. 5. Differential FGFR clustering by different ligand combinations. MCF-7 cells were exposed to different FGF/HSGAG combinations
for 60 min in the presence of the cross-linker DSS; lysed; and then immunoprecipitated with anti-FGFR1, anti-FGFR2, anti-FGFR3, or anti-FGFR4
antibodies against a control (Con) of no antibodies (noA) and then subjected to 5% SDS-PAGE. Gels were electroblotted and autoradiographed, and
the bands were analyzed. The bands are complexes of FGF, FGFR, and HS and ran just under 300 kDa. A, radiolabeled cells were exposed to no
growth factor (i.e. DSS alone), FGF-2 alone, or FGF-1 alone (left panel) or to HSGAGB alone, FGF-2/HSGAGB, or FGF-1/HSGAGA (right panel).
Note how the presence of sugar restricted the receptor coupling. B, non-radiolabeled MCF-7 cells in suspension were exposed to the FGF/HS
combinations for 60 min and lysed as described above. Lysates were incubated with anti-FGFR antibodies, immunoprecipitated, and subjected to
SDS-PAGE. Gels were electroblotted, and the membranes were probed with anti-phosphotyrosine monoclonal antibody 4G10 prior to fluorimaging.
R1, FGFR1.
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231 cells. It is important to note that the highly motile MDA-
MB-231 cells had to be pretreated with heparitinase I to re-
move endogenous inhibitory HS sequences that would
otherwise depress the responses to our exogenous HS chal-
lenge, consistent with previous results (28).
The proliferation assays demonstrated that FGF-2 with HS-
GAGB proved to be a better mitogenic stimulus than FGF-1/
HSGAGA for all cell types. The growth of breast cancer cells
can be regulated by a large variety of peptide factors, including
transforming growth factors b and nerve growth factor, as well
as by retinoic acid and sodium butyrate (45, 46). HS is abun-
dant within breast tissue, as are the FGFs, although it is highly
probable that other heparin-binding growth factor classes con-
tribute to the mitogenic environment (47, 48). Clearly, the
balance between these highly complex systems will dictate the
phenotypic behavior of these cells.
These results cannot be explained by differential receptor
expression, as both MCF-7 and MDA-MB-231 cells express
forms of each of FGFR1, FGFR2, FGFR3, and FGFR4 (49),
albeit at different levels. The major differences were seen be-
tween the relative message levels of FGFR1 and FGFR2 on the
MCF-7 and MDA-MB-231 cells. For the MCF-7 cells, the recep-
tor profiles were substantially similar for both the IIIb and IIIc
forms, whereas the MDA-MB-231 cells expressed markedly
more of the FGFR2 IIIc form than the FGFR2 IIIb form. It
remains hard to understand exactly what this means, however,
FIG. 6. Quantitation of in vitro
MAPK tyrosine phosphorylation in
MCF-7 and MDA-MB-231 cells ex-
posed to different FGF/HS combina-
tions. MAPK activity was determined by
immunoprecipitation of lysates with anti-
ERK1 and anti-ERK2 antibodies and re-
vealed on gels with anti-phosphotyrosine
monoclonal antibody 4G10. The phospho-
rylated ERK bands were visualized by
fluorimaging, and the density of the
bands was quantitated; each treatment
thus resulted in a double band. A, MCF-7
cells (with one of the three sets of gels
that were quantitated above); B, native
MDA-MB-231 cells (black bars) and hep-
aritinase I-treated MDA-MB-231 cells
(white bars; with one of the three sets of
gels that were quantitated above). Each
bar represents the mean 6 S.D. of three
replicate cell preparations. Con, control.
FIG. 7. Quantitation of in vitro Src
kinase activity in MCF-7 and MDA-
MB-231 cells exposed to different
FGF/HS combinations for 4 h. Src ki-
nase activity was determined by immuno-
precipitation with anti-Src monoclonal
antibody 327, and in vitro kinase assays
were performed using enolase as a sub-
strate (34). The density of the enolase
bands was then quantitated using cali-
brated densitometry. One of the three
sets of gels that were quantitated is
shown above each histogram. A, MCF-7
cells; B, native MDA-MB-231 cells (black
bars) and heparitinase I-treated MDA-
MB-231 cells (white bars). Each bar rep-
resents the mean 6 S.D. of three replicate
cell preparations. Con, control.
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as it has not yet been possible to correlate isoforms definitively
with phenotypic outcomes. The problem is compounded by the
fact that cells need only use a small fraction of their high
affinity receptors on their surfaces to activate signaling cas-
cades that profoundly influence their subsequent behaviors
(50).
Another difference between the motile and proliferative cell
types was that MCF-7 cells had a far greater proportion of its
FGFR1 expressed in shorter two-Ig loop b forms than full-
length three-Ig loop a forms. Although the two immunoglobulin
loops that compose the b isoform appear to be sufficient for
ligand binding (where the ligand consists of FGF/HS), the
N-terminal loop of the three-loop a isoform can interact with
the two-loop ligand-binding site (51, 52). We have not yet
detected such heterodimeric interactions in our assays. Our
assay did not distinguish between receptor variants that might
have foreshortened tyrosine kinase domains at their intracel-
lular C-terminal ends, such as has been seen for liver cells
lacking a complete catalytic domain and the two major intra-
cellular tyrosine autophosphorylation sites Tyr-653 and Tyr-
766 (51). Dimerization of monomers arising from regulated
combinatorial splicing of coding sequences for the extracellular
domains and the intracellular kinase domains from a single
FGFR gene is thought to explain the concentration-dependent
effects of a single FGF ligand on growth within a single cell
type (35). Our results demonstrate a correlation between
shorter forms of FGFR and growth responses through the as-
sociation of HSGAGB and FGF-2. This result is consistent with
those that showed that the loss of expression of the a exon of
the FGFR2 gene in normal rat prostate epithelial cells also
correlates with malignancy due to the increased binding of
potentiating forms of HS to the shorter receptors (53). We do
not believe that we have a spurious association of HS and
FGFR where, for example, HSGAGB randomly binds more of
the FGFR1 in MCF-7 cells because there is simply more of this
receptor species than any other. The same was true for HS-
GAGB and MDA-MB-231 cells, in which the FGFR2 form
predominated.
Our receptor activation studies demonstrate that the two
different HSGAGs bring different combinations of FGFRs into
activating complexes. Oligomerization and, most important,
dimerization of the monomeric protein subunits (22) of tyrosine
kinase transmembrane receptors facilitate transphosphoryla-
tion of tyrosines within the substrate-binding and catalytic
intracellular domains. This is obligatory for the subsequent
activation of second messenger substrates of the SH2, Grb2,
Ras, and phospholipase Cg domain classes (54). Our results
confirm the idea that the enforced clustering of different pro-
portions of FGFRs by specific HS sequences leads to different
phenotypic outcomes. From these results, we would predict
that HSGAGB-triggered FGFR1 homodimerization or higher
order oligomerization favors the activation of the MAPK path-
way. In contrast, we would predict that the clustering of
FGFR1 and FGFR2 oligomers leads to quantitatively different
transphosphorylation events that favor not only proliferation,
but also the activation of Src and its downstream target FAK.
MAPKs are activated rapidly in response to a great variety of
extracellular stimuli, including mitogens, heat shock, neuro-
transmitters, and phorbol esters (55). Our work has a compli-
cated relationship with some previously described. Removal of
FGF-1 from the culture medium of fibroblasts is sufficient to
reverse the tyrosine phosphorylation of FGFR1 and the MAPK
pathway, events that correlate with reductions in FGF-1-in-
duced DNA synthesis (35). A transient exposure of just a few
hours for these cells results in a sustained activation of the
FGF-1-induced Src pathway, leading to changes in the cy-
toskeleton that maintain migratory potential. These experi-
ments are not altogether easy to interpret, however, as FGF-1
FIG. 8. Immunoblot analysis of FAK
tyrosine phosphorylation in MCF-7
and MDA-MB-231 cells exposed to dif-
ferent FGF/HS combinations for 4 h.
The activity of FAK was assessed by im-
munoprecipitation and immunoblotting
with anti-phosphotyrosine monoclonal
antibody 4G10. The phosphorylated FAK
was visualized by fluorimaging, and the
density of the bands was quantitated.
One of the three sets of gels that were
quantitated is shown above each histo-
gram. A, MCF-7 cells; B, native MDA-
MB-231 cells (black bars) and hepariti-
nase I-treated MDA-MB-231 cells (white
bars). Each bar represents the mean 6
S.D. of three replicate cell preparations.
Con, control.
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was presented in association with heparin, which may cross-
link a vast series of physiologically irrelevant heparin-binding
molecules. In particular, it can carry FGF-1 to every variant
form of FGFR. In our case, HSGAGA seems to mimic the effects
of transient FGF-1 exposure, perhaps by controlling the rate of
access of FGF-1 to its receptor.
The receptor tyrosine kinase-mediated Ras/Raf/MAPK path-
way, which eventually leads to the up-regulation of Fos (56)
and Myc (57), is currently thought to be essential for cell
replication. However, it is becoming clear that there are com-
plicated relationships between particular cell types, particular
mitogens, and subsequent activity in the nucleus. Epidermal
growth factor-induced scattering of epithelial cells appears to
be dependent only on Src, and not on Myc (58); however, when
3T3 fibroblasts are exposed to platelet-derived growth factor,
Src does activate Myc (59). FGF-1 activates Src and Fos in
umbilical endothelial cells, but not in senescent endothelial
cells (60, 61). Src strongly associates with FAK near focal
adhesion plaques (62), and cells from FAK knockout mice show
poor migratory behaviors (63). Our data support the idea that
HSGAGA, through differential receptor association, leads to a
bifurcation of the FGF-1 signal into separable migratory and
mitogenic pathways; this signaling is not seen with signaling
through FGFR1 alone. It is also not immediately clear why
FGF-2/HSGAG is more inhibitory for Src kinase activity in
normal rather than heparitinase I-treated cells (Fig. 7). The
result implies that the endogenous inhibitory and exogenous
stimulatory GAGs somehow combine to disrupt a receptor-
mediating pathway that results in Src regulation.
As phosphorylated FAK strongly associates with matrix re-
ceptors (62, 64), our last experiments were directed toward
which integrin a and b subunit combinations might be acti-
vated by FGF-1/HSGAGA. The FGFR1/FGFR1-utilizing
MCF-7 cells use a different complement of integrins to migrate
than the FGFR1/FGFR2-utilizing MDA-MB-231 cells. The for-
mer use the laminin receptor a6b1, whereas the latter primar-
ily use the vitronectin receptor avb3. This result extends pre-
vious results demonstrating the avid attachment of breast cells
to vitronectin substrates (44, 65). Breast cells have a large
variety of integrin dimers on their surfaces for binding to
matrix components (43), but primarily utilize avb1, avb3, and
avb5 for vitronectin (66). Our results are interesting because
avb3 activation correlates with high rather than low malignant
potential (65, 67). We conclude that the different species of
FGF-specific HS can couple different combinations of FGFR to
drive particular phenotypic outcomes. As active HS domains
FIG. 9. Specificity in the adhesion
signals triggered by FGF-1/HSGAGA.
MCF-7 and MDA-MB-231 cells were
plated onto Matrigel substrates and ex-
posed to soluble FGF/HSGAGA (5 ng/ml
FGF-1 with 5 mg/ml HSGAGA) and spe-
cific integrin-blocking antibodies (100 mg/
ml) for 150 min while their movements
were monitored by time-lapse photomi-
crography. A, distance traveled by MCF-7
cells. The controls consisted of no addi-
tives (Con), FGF-1 (5 ng/ml) by itself, and
the incorrect pairing FGF-1/HSGAGB. B,
distance traveled by MDA-MB-231 cells.
C, effect of FGF-1/HSGAGA on the migra-
tion of MCF-7 cells (l ) and MDA-MB-231
cells (E) on various concentrations of
laminin. Each point represents the
mean 6 S.D. of three replicate wells and
at least 150 cells. D, the same experiment
using vitronectin as the substrate. Note
the change of scale.
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can be split into smaller fragments that can act as competitive
inhibitors, this work may help lead to the discovery of HS
fragments with which to control the cellular behavior of breast
tumor cells.
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